Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.94 +0.08 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
News headline image
OTC Markets Hits Major Milestones in Mid-Year Along With Big Volume and Gaining Securities ↗
Photo by Kyrie Kim on Unsplash In a similar vein to 2020, the market’s volatility to start 2021 gave way to less volatility in the second quarter, and even less volatility... 
Via Benzinga
News headline image
Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings ↗
Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49... 
Via Benzinga
News headline image
Joblessness Surprise ↗
Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices. 
Via Talk Markets
News headline image
Roche Puts Alzheimer's Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters ↗
Roche Holding AG (OTC: RHHBY) is reportedly talking to the FDA about its Alzheimer’s disease drug candidate, gantenerumab. CEO Severin Schwan declined... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021 ↗
Upgrades According to Stephens & Co., the prior rating for World Acceptance Corp (NASDAQ:... 
Via Benzinga
News headline image
Rebound In COVID-19 Tests Lift Roche's Half-Year Sales, Oncology Still Hit By Biosimilars, Pandemic ↗
Roche Holding AG's (OTC: RHHBY) 1H 2021 sales increased by 8% Y/Y at constant exchange rates (CER) to CHF 30.7 billion as peak demand for COVID-19 tests helped... 
Via Benzinga
News headline image
Panic Attack ↗
The H1 rise in US markets was based on hope for an end to lockdowns. 
Via Talk Markets
News headline image
Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression ↗
Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced updated data from the ongoing Phase 1/2 trial of SPK-8011 gene therapy in... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
News headline image
AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes ↗
The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with azacitidine for the potential treatment of adult patients with... 
Via Benzinga
News headline image
FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
From Genentech
Via Business Wire
News headline image
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A ↗
According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A... 
Via Benzinga
News headline image
New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A
From Genentech
Via Business Wire
News headline image
Biogen Stock And The Aduhelm Drama: Will It Really Treat Alzheimer's? ↗
The fate of Biogen stock is now intricately tied to the success — or failure — of its controversial Alzheimer's treatment, Aduhelm. 
Via Investor's Business Daily
News headline image
5 Stocks to Own for the Surge in Coronavirus Variants ↗
Despite easing restrictions, COVID is going to be around a lot longer than many think. 
Via The Motley Fool
News headline image
Yellow Card ↗
The price of oil fell about 1% today. 
Via Talk Markets
News headline image
Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159 ↗
Celldex Therapeutics Inc (NASDAQ: CLDX) got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021 ↗
Upgrades For FB Financial Corp (NYSE: 
Via Benzinga
News headline image
WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients ↗
The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients... 
Via Benzinga
News headline image
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today ↗
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ:... 
Via Benzinga
News headline image
New Month And Half Year ↗
Welcome to H2. In theory, if markets did well in H1 they tend to close the year up. 
Via Talk Markets
News headline image
End Of June ↗
Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made. 
Via Talk Markets
Topics Initial Public Offering
News headline image
Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-... 
Via Benzinga
News headline image
Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact ↗
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it... 
Via Benzinga
Topics Intellectual Property
News headline image
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer ↗
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (... 
Via Benzinga
News headline image
Roche's Enspryng Wins European Approval For Spinal Cord, Optic Nerve Inflammation Disorder ↗
The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder... 
Via Benzinga
News headline image
FDA Gives Emergency Use Nod For Roche's Arthritis Drug Against Severe COVID-19 ↗
The 
Via Benzinga
News headline image
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
News headline image
Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children
From Genentech
Via Business Wire
News headline image
Crazy Thursday ↗
Today the US stock market went ballistic probably because of a higher joblessness level than expected. 
Via Talk Markets
< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.